Clinical trials: Sirolimus
Recurrent Childhood Ependymoma
Everolimus for Children With Recurrent or Progressive Ependymoma
The purpose of this study is to evaluate the anti-tumor activity of Everolimus among children with recurrent or progressive ependymoma. Recurrent or progressive ependymoma is incurable and has very limited treatment options.
- Trial name
- NCT02155920
- Testing
- Everolimus
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- University of Texas Southwestern Medical Center
Breast Cancer
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
This is an open-label, single arm, multi-center, multi-national, adaptive design, dose-escalation Phase 1/2 study to determine the maximum tolerated dose (MTD) of temsirolimus with daily neratinib, and to determine the safety and…
- Trial name
- NCT01111825
- Testing
- Temsirolimus, Neratinib
- Where
- 12 sites in United States, Denmark and 4 more
- Volunteers
- 99 people
- Sponsor
- Puma Biotechnology, Inc.
Myeloma, Plasma-Cell, Myeloma-Multiple
Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma
Background: Cancer development is associated with problems in immune system functions, which prevent the body from attacking and destroying the abnormal cells that lead to tumor growth.
- Conditions
- Myeloma, Plasma-Cell, Myeloma-Multiple, Myelomatosis
- Trial name
- NCT01239368
- Testing
- Adoptive Immunotherapy, Rapamycin-Generated Autologous Th1/Tc1 Cells (modified primary human T cells), Th1/Tc1 Rapa Cell Therapy
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Melanoma, Stage IIIB Skin Melanoma
Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma
This phase II trial is studying how well giving temsirolimus together with bevacizumab works in treating patients with stage III or stage IV malignant melanoma.
- Conditions
- Recurrent Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
- Trial name
- Mel47 (NCT00397982)
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Temsirolimus
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Renal Transplant Rejection
Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients
This study is being done to investigate the impact of changing immunosuppressive medications from tacrolimus (Prograf®) to sirolimus (Rapamune®) between 6 and 24 months post transplant.
- Trial name
- NCT00866879
- Testing
- Sirolimus, Demographic Data, Medical History, and Donor Data, Blood Draws for Control Group
- Where
- United States
- Volunteers
- 275 people
- Sponsor
- Northwestern University
Carcinoid Tumor, Malignant Carcinoid Syndrome
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
The purpose of this study was to evaluate whether everolimus 10 mg / day added to treatment with depot octreotide prolongs progression free survival compared to treatment with octreotide alone in patients with advanced carcinoid…
- Trial name
- RADIANT-2 (NCT00412061)
- Testing
- Octreotide, Everolimus
- Where
- 70 sites in United States, Australia and 13 more
- Volunteers
- 429 people
- Sponsor
- Novartis Pharmaceuticals
Malignant PEComa
A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa
A phase 2 multi-center investigation of efficacy of nab-sirolimus (formerly known as ABI-009 or nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumor (PEComa).
- Trial name
- AMPECT (NCT02494570)
- Testing
- nab-Sirolimus
- Where
- 9 sites in United States
- Volunteers
- 34 people
- Sponsor
- Aadi Bioscience, Inc.
Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Complete Remission
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
This phase Ib/2 trial studies how well chemotherapy, total body irradiation, and post-transplant cyclophosphamide work in reducing rates of graft versus host disease in patients with hematologic malignancies undergoing a donor…
- Conditions
- Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Complete Remission, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Chronic Myelomonocytic Leukemia in Remission
- Trial name
- NCT03192397
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Roswell Park Cancer Institute
Neoplasms
BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer
Phase Ib / II study to determine the Maximum Tolerated Dose and Recommended Phase II Dose, and to evaluate the safety and antitumour activity, of BI 836845 and everolimus in combination with exemestane in women with HR+/HER2…
- Trial name
- NCT02123823
- Testing
- Everolimus, Exemestane, BI 836845
- Where
- 38 sites in Austria, Belgium and 8 more
- Volunteers
- 164 people
- Sponsor
- Boehringer Ingelheim
Sarcoma
Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas
The goal of this clinical research study is to learn if the study drug RAD001 can stop or slow the growth of resectable soft tissue sarcoma.
- Trial name
- NCT01048723
- Testing
- RAD001
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
TSC1, TSC2
Everolimus for Cancer With TSC1 or TSC2 Mutation
In this research study, the investigators are evaluating the clinical benefit of everolimus in cancer patients with inactivating TSC1 or TSC2 mutations or activating MTOR mutations.
- Conditions
- TSC1, TSC2, Tuberous Sclerosis Complex, MTOR
- Trial name
- NCT02201212
- Testing
- Everolimus
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Recurrent Melanoma, Stage IV Melanoma
Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
This randomized phase II trial is studying how well giving sorafenib together with either temsirolimus or tipifarnib works in treating patients with stage IV melanoma that cannot be removed by surgery.
- Trial name
- NCT00281957
- Testing
- sorafenib tosylate, tipifarnib, temsirolimus
- Where
- 173 sites in United States
- Volunteers
- 109 people
- Sponsor
- National Cancer Institute (NCI)
Tuberous Sclerosis Complex
Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)
Tuberous Sclerosis Complex (TSC) is a multi-system disease, usually presenting with seizures, mental retardation and autism, and exhibiting a high variability in clinical findings both among and within families.
- Trial name
- TSC (NCT01289912)
- Testing
- RAD001
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- Mustafa Sahin
Renal Cell Carcinoma, Kidney Cancer
Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
This is a single-arm phase II trial evaluating the combination of avastin and temsirolimus in patients with metastatic renal cell cancer (RCC) including both histologically confirmed clear cell (cc) or non-clear cell (ncc)…
- Trial name
- NCT00782275
- Testing
- bevacizumab, temsirolimus
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Beth Israel Deaconess Medical Center
Advanced Breast Cancer
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer
Open-label, Phase II study of Stomatitis prevention with a steroid-based mouthwash in Post-menopausal women with ER+, HER2- Metastatic or Locally Advanced Breast Cancer
- Trial name
- NCT02069093
- Testing
- Dexamethasone based mouthwash, Everolimus, Exemestane
- Where
- 23 sites in United States
- Volunteers
- 92 people
- Sponsor
- Novartis Pharmaceuticals
Liver Transplantation
Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy
The study is designed to show that everolimus initiation together with reduction and thereafter discontinuation of calcineurin inhibitor (CNI) will improve significantly renal function in de novo liver transplant recipients as…
- Trial name
- NCT00378014
- Testing
- everolimus, basiliximab, CNI
- Where
- 16 sites in Austria, Germany and 2 more
- Volunteers
- 276 people
- Sponsor
- Novartis Pharmaceuticals
Epilepsy, Tuberous Sclerosis Complex
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)
The goal of this study is to learn if the study drug RAD001 can reduced the number of epileptic seizures, and can be taken safety by people who have epilepsy associated with Tuberous Sclerosis Complex.
- Trial name
- NCT01070316
- Testing
- Everolimus
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Renal Transplantation
Study Evaluating Conversion From Tacrolimus to Sirolimus in Stable Kidney Transplant Recipients Receiving Myfortic
The purpose of this study is to determine whether the combination of Myfortic and sirolimus is effective at preventing rejection while preserving kidney function in stable kidney transplant recipients.
- Trial name
- MYFIIRP (NCT00713284)
- Testing
- sirolimus
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- California Pacific Medical Center Research Institute
Kidney Failure, Chronic, Kidney Transplantation
Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients
The purpose of this study is to evaluate the safety of alemtuzumab after kidney transplantation as part of a multitherapy regimen to prevent kidney graft loss and death and to avoid steroids and chronic use of calcineurin…
- Conditions
- Kidney Failure, Chronic, Kidney Transplantation, Immunosuppression
- Trial name
- NCT00240994
- Testing
- Alemtuzumab, Tacrolimus, Mycophenolate mofetil
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pancreatic Cancer
Sirolimus in Treating Patients With Advanced Pancreatic Cancer
RATIONALE: Sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well sirolimus works in treating patients with advanced pancreatic…
- Trial name
- NCT00499486
- Testing
- sirolimus
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins